Delving into the Latest Updates on NPO-2270 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target-

Mechanism-

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Postmyocardial infarction syndrome

Inactive Indication-

Originator Organization

Landsteiner Genmed

Active Organization

Landsteiner Genmed

Inactive Organization-

Drug Highest PhaseDiscovery

First Approval Date-

Regulation-

Cysteine proteases calpains contribute to heart failure (HF), but it remains unknown whether their inhibition provides any benefit compared to standard pharmacological treatment for HF. Here, we characterize the pharmacological properties of NPO-2270 (NPO) as a potent inhibitor of cysteine proteases. Then, we describe that acute administration of NPO in rodent models of transient ischemia at the time of reperfusion reduces myocardial infarction, while its chronic oral administration attenuates adverse remodeling and cardiac dysfunction induced by ischemic and non-ischemic pathological stimuli more effectively than enalapril when given at the same dose. Finally, we provide evidence showing that the effects of NPO correlate with calpain inhibition and the preservation of the T-tubule morphology, due at least in part to reduced cleavage of the calpain substrate junctophilin-2. Together, our data highlight the potential of cysteine protease inhibition with NPO as a therapeutic strategy for the treatment of heart failure.

100 Deals associated with NPO-2270

Login to view more data